---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-016657"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T01:02:07.278909+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Graphite Bio doses first patient with nula-cel for sickle cell disease; proof-of-concept data mid-2023

## Summary
- First patient dosed with nula-cel (formerly GPH101) in Phase 1/2 CEDAR trial for sickle cell disease.
- Nula-cel is a gene editing therapy designed to directly correct the SCD mutation and restore healthy hemoglobin.
- Initial proof-of-concept data from the CEDAR trial expected in mid-2023.
- FDA granted Fast Track and Orphan Drug designations for nula-cel.
- Phase 1/2 trial to enroll ~15 patients with severe SCD at multiple U.S. sites.

## SEC filing metadata
- accession: 0000950170-22-016657
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000095017022016657/0000950170-22-016657-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000095017022016657/grph-20220811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-016657
- JSON: https://secwatch.observer/filing/0000950170-22-016657.json
- Plain text: https://secwatch.observer/filing/0000950170-22-016657.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.